{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-036247","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2024-11-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.884441+00:00","generated_at":"2026-05-29T17:32:50.072685+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Dyadic receives $3.1M Gates Foundation grant for RSV and malaria mAb development","bullets":["Grant of $3,092,136 from Bill & Melinda Gates Foundation for monoclonal antibody development using C1 platform.","Targets RSV (100K+ deaths annually, 99% in LMICs) and malaria (249M cases, 608K deaths in 2022).","Aims to reduce production costs and improve global access to affordable therapeutics for underserved populations.","Dyadic plans to commercialize resulting antibodies via licensure if development succeeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-036247","json":"https://secwatch.observer/filing/0001437749-24-036247.json","markdown":"https://secwatch.observer/filing/0001437749-24-036247.md","text":"https://secwatch.observer/filing/0001437749-24-036247.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000143774924036247/0001437749-24-036247-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000143774924036247/dyai20241120_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T17:32:50.072685+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}